114 related articles for article (PubMed ID: 27957707)
21. The potential benefit of endothelin receptor antagonists' therapy in idiopathic pulmonary fibrosis: A meta-analysis of results from randomized controlled trials.
Li S; Pan YL; Xin W; Yan C
Medicine (Baltimore); 2022 Oct; 101(40):e29981. PubMed ID: 36221345
[TBL] [Abstract][Full Text] [Related]
22. Relations of Anemia With the All-Cause Mortality and Cardiovascular Mortality in General Population: A Meta-Analysis.
Liu Z; Sun R; Li J; Cheng W; Li L
Am J Med Sci; 2019 Sep; 358(3):191-199. PubMed ID: 31331612
[TBL] [Abstract][Full Text] [Related]
23. The new era of clinical research: using data for multiple purposes.
Califf RM
Am Heart J; 2014 Aug; 168(2):133-4. PubMed ID: 25066550
[No Abstract] [Full Text] [Related]
24. Endothelin receptor antagonists and cardiovascular disease.
Jarvis B; Duff R; Elkinson S
Drugs R D; 1999 Jul; 2(1):13-6. PubMed ID: 10610274
[No Abstract] [Full Text] [Related]
25. Erratum to: Effects of SGLT-2 inhibitors on mortality and cardiovascular events: a comprehensive meta-analysis of randomized controlled trials.
Monami M; Dicembrini I; Mannucci E
Acta Diabetol; 2017 Jan; 54(1):37-38. PubMed ID: 27730308
[No Abstract] [Full Text] [Related]
26. Treatment of anaemia in the "ERAS" era: how far can we go?
Rolli L; Duranti L; Leuzzi G
J Thorac Dis; 2019 Sep; 11(9):3692-3695. PubMed ID: 31656640
[No Abstract] [Full Text] [Related]
27. ERAS - The dawn of a new era!
Gopinath R; Belani KG
J Anaesthesiol Clin Pharmacol; 2019 Apr; 35(Suppl 1):S1-S2. PubMed ID: 31142951
[No Abstract] [Full Text] [Related]
28. Are randomized trials obsolete or more important than ever in the genomic era?
Ioannidis JP; Khoury MJ
Genome Med; 2013; 5(4):32. PubMed ID: 23673134
[No Abstract] [Full Text] [Related]
29. Cardiovascular Diseases: A Challenge for the New Era.
Borrayo-Sánchez G; González-Juanatey JR
Arch Med Res; 2018 Nov; 49(8):515. PubMed ID: 30718150
[No Abstract] [Full Text] [Related]
30. A New Era of Targeting Pathogenic Immune Mechanisms in Cardiovascular Disease.
Park MS; Youn JC
Korean Circ J; 2018 Oct; 48(10):944-946. PubMed ID: 30238712
[No Abstract] [Full Text] [Related]
31. Clinical study of right ventricular longitudinal strain for assessing right ventricular dysfunction and hemodynamics in pulmonary hypertension.
Li Y; Wang Y; Ye X; Kong L; Zhu W; Lu X
Medicine (Baltimore); 2016 Dec; 95(50):e5668. PubMed ID: 27977616
[TBL] [Abstract][Full Text] [Related]
32. A Review of Clinical Trial Endpoints of Patients with Pulmonary Arterial Hypertension and Chronic Thromboembolic Pulmonary Hypertension and How They Relate to Patient Outcomes in the United States.
Divers C; Platt D; Wang E; Lin J; Lingohr-Smith M; Mathai SC
J Manag Care Spec Pharm; 2017 Jan; 23(1):92-104. PubMed ID: 28025931
[TBL] [Abstract][Full Text] [Related]
33. Statins Have No Additional Benefit for Pulmonary Hypertension: A Meta-Analysis of Randomized Controlled Trials.
Wang L; Qu M; Chen Y; Zhou Y; Wan Z
PLoS One; 2016; 11(12):e0168101. PubMed ID: 27992469
[TBL] [Abstract][Full Text] [Related]
34. A simple hemodynamic parameter to predict clinical worsening in pulmonary arterial hypertension.
Amin A; Mohamadifar A; Keshmiri MS; Ghadrdoost B; Taghavi S; Naderi N
J Crit Care; 2017 Apr; 38():324-327. PubMed ID: 27988069
[TBL] [Abstract][Full Text] [Related]
35. Evidence synthesis in pulmonary arterial hypertension: a systematic review and critical appraisal.
Schlueter M; Beaudet A; Davies E; Gurung B; Karabis A
BMC Pulm Med; 2020 Jul; 20(1):202. PubMed ID: 32723397
[TBL] [Abstract][Full Text] [Related]
36. Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials.
Pan Y; Hu C; Chen PH; Gu YH; Qiao QY; Pan LH; Zhou DC; Gu HF; Fu SK; Jin HM
Eur J Clin Pharmacol; 2017 Mar; 73(3):267-278. PubMed ID: 27957707
[TBL] [Abstract][Full Text] [Related]
37. Clinical Adverse Effects of Endothelin Receptor Antagonists: Insights From the Meta-Analysis of 4894 Patients From 24 Randomized Double-Blind Placebo-Controlled Clinical Trials.
Wei A; Gu Z; Li J; Liu X; Wu X; Han Y; Pu J
J Am Heart Assoc; 2016 Oct; 5(11):. PubMed ID: 27912207
[TBL] [Abstract][Full Text] [Related]
38. Oral targeted therapies in the treatment of pulmonary arterial hypertension: a meta-analysis of clinical trials.
Zheng YG; Ma H; Hu EC; Liu G; Chen G; Xiong CM
Pulm Pharmacol Ther; 2014 Dec; 29(2):241-9. PubMed ID: 25173912
[TBL] [Abstract][Full Text] [Related]
39. Pharmacotherapy in pulmonary arterial hypertension: a systematic review and meta-analysis.
Ryerson CJ; Nayar S; Swiston JR; Sin DD
Respir Res; 2010 Jan; 11(1):12. PubMed ID: 20113497
[TBL] [Abstract][Full Text] [Related]
40. Effects of glucose-lowering and multifactorial interventions on cardiovascular and mortality outcomes: a meta-analysis of randomized control trials.
Seidu S; Achana FA; Gray LJ; Davies MJ; Khunti K
Diabet Med; 2016 Mar; 33(3):280-9. PubMed ID: 26282461
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
